Germany · Delayed Price · Currency is EUR Rhythm Pharmaceuticals Company Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
The company was founded in 2008 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 283 |
| CEO | David Meeker |
Contact Details
Address: 222 Berkeley Street Boston, Delaware 02116 United States | |
| Phone | 857 264 4280 |
| Website | rhythmtx.com |
Stock Details
| Ticker Symbol | 1RV |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Meeker | Chief Executive Officer |
| Hunter Smith | Chief Financial Officer |
| David Connolly | Head of Investor Relations |